YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma

References

• Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet. 2015;385(9983):2197–2208.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48–e548.
   PubMed Web of Science ®Google Scholar
• Alzrigat M, Párraga AA, Jernberg-Wiklund H. Epigenetics in multiple myeloma: from mechanisms to therapy. Semin Cancer Biol. 2018;51:101–115.
   PubMed Web of Science ®Google Scholar
• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.
   PubMed Web of Science ®Google Scholar
• Kapranov P, Cheng J, Dike S, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007;316(5830):1484–1488.
   PubMed Web of Science ®Google Scholar
• Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23(13):1494–1504.
   PubMed Web of Science ®Google Scholar
• Chen LL, Carmichael GG. Long noncoding RNAs in mammalian cells: what, where, and why? Wiley Interdiscip Rev RNA.2010; 1(1):2–21.
   PubMed Web of Science ®Google Scholar
• Zhang H, Xu R, Li B, et al. LncRNA NEAT1 controls the lineage fates of BMSCs during skeletal aging by impairing mitochondrial function and pluripotency maintenance. Cell Death Differ. 2022;29(2):351–365.
   PubMed Web of Science ®Google Scholar
• Shi L, Yang Y, Li M, et al. LncRNA IFITM4P promotes immune escape by up-regulating PD-L1 via dual mechanism in oral carcinogenesis. Mol Ther. 2022;30(4):1564–1577.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Ji H, Jeong SD, et al. LINC00162 regulates cell proliferation and apoptosis by sponging PAQR4-targeting miR-485-5p. J Cell Physiol. 2022;237(7):2943–2960.
   PubMed Web of Science ®Google Scholar
• Sharma U, Kaur Rana M, Singh K, et al. LINC00324 promotes cell proliferation and metastasis of esophageal squamous cell carcinoma through sponging miR-493-5p via MAPK signaling pathway. Biochem Pharmacol. 2023;207:115372.
   PubMed Web of Science ®Google Scholar
• Silva-Fisher JM, Dang HX, White NM, et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nat Commun. 2020;11(1):2156.
   PubMed Web of Science ®Google Scholar
• Taiana E, Bandini C, Favasuli VK, et al. Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins. Haematologica. 2023;108(1):219–233.
   PubMedGoogle Scholar
• Young TL, Matsuda T, Cepko CL. The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina. Curr Biol. 2005;15(6):501–512.
   PubMed Web of Science ®Google Scholar
• Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009;106(28):11667–11672.
   PubMed Web of Science ®Google Scholar
• van Kruijsbergen I, Hontelez S, Veenstra GJ. Recruiting polycomb to chromatin. Int J Biochem Cell Biol. 2015; 67:177–187.
   PubMed Web of Science ®Google Scholar
• Azizidoost S, Nasrolahi A, Ghaedrahmati F, et al. The pathogenic roles of lncRNA-Taurine upregulated 1 (TUG1) in colorectal cancer. Cancer Cell Int. 2022;22(1):335.
   PubMed Web of Science ®Google Scholar
• Liu W, Meng J, Su R, et al. SP1-mediated up-regulation of lncRNA TUG1 underlines an oncogenic property in colorectal cancer. Cell Death Dis. 2022;13(5):433.
   PubMed Web of Science ®Google Scholar
• Wang P, Yang Z, Ye T, et al. lncTUG1/miR-144-3p affect the radiosensitivity of esophageal squamous cell carcinoma by competitively regulating c-MET. J Exp Clin Cancer Res. 2020;39(1):7.
   PubMed Web of Science ®Google Scholar
• Yin Q, Shen X, Cui X, et al. Elevated serum lncRNA TUG1 levels are a potential diagnostic biomarker of multiple myeloma. Exp Hematol. 2019;79:47–55.e2.
   PubMed Web of Science ®Google Scholar
• van de Donk N, Pawlyn C, Yong KL. Multiple myeloma.  Lancet. 2021;397(10272):410–427.
   PubMed Web of Science ®Google Scholar
• Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the international myeloma working group. Lancet Oncol. 2021;22(3):e105–e118.
   PubMed Web of Science ®Google Scholar
• Das S, Juliana N, Yazit NAA, et al. Multiple myeloma: challenges encountered and future options for better treatment. IJMS. 2022;23(3):1649.
   Google Scholar
• Li J, Zou J, Wan X, et al. Roles of noncoding RNAs in drug resistance in multiple myeloma. J Cell Physiol. 2020;235(11):7681–7695.
   PubMed Web of Science ®Google Scholar
• Fu Y, Liu X, Zhang F, et al. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b. Cell Death Dis. 2019;10(4):319.
   PubMedGoogle Scholar
• Lu D, Yang C, Zhang Z, et al. Knockdown of Linc00515 inhibits multiple myeloma autophagy and chemoresistance by upregulating miR-140-5p and downregulating ATG14. Cell Physiol Biochem. 2018;48(6):2517–2527.
   PubMedGoogle Scholar
• Bär C, Chatterjee S, Thum T. Long noncoding RNAs in cardiovascular pathology, diagnosis, and therapy. Circulation. 2016;134(19):1484–1499.
   PubMed Web of Science ®Google Scholar
• Sarvagalla S, Kolapalli SP, Vallabhapurapu S. The two sides of YY1 in cancer: a friend and a foe. Front Oncol. 2019;9:1230.
   PubMed Web of Science ®Google Scholar
• Ernst R, Mueller B, Ploegh HL, et al. The otubain YOD1 is a deubiquitinating enzyme that associates with p97 to facilitate protein dislocation from the ER. Mol Cell. 2009;36(1):28–38.
   PubMed Web of Science ®Google Scholar
• Pu J, Xu Z, Nian J, et al. M2 macrophage-derived extracellular vesicles facilitate CD8 + T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/Yap/β-catenin pathway. Cell Death Discov. 2021;7(1):182.
   PubMed Web of Science ®Google Scholar